Cannabinoid treatment to lower inflammation and sickle pain
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This Phase 2 study tests a cannabinoid medicine (dronabinol) to reduce inflammation and pain related to sickle cell disease. It may help you have less pain that interferes with daily life if you meet the study requirements and can safely avoid cannabis during the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have a confirmed diagnosis of sickle cell disease (including HbSS, HbSC, or certain Hb variants)
- Your pain interference score must be 60 or lower on an approved 7-day questionnaire
- If you take sickle cell medicines or pain medicines at home, doses must be stable for at least 3 months
- You must test negative for cannabinoids in a urine test within 30 days and agree to avoid all cannabis during weeks 1–8
- You must be able to use safe birth control if you could become pregnant, and you cannot be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if cannabidiol (CBD) can help reduce pain interference in adults with sickle cell disease. You will take CBD daily for 4 weeks and report your pain levels.
This trial tests whether adding acupuncture to standard pain treatments can help manage pain in people with sickle cell disease. It involves brain scans, questionnaires, and acupuncture sessions to see if this approach reduces pain and improves quality of life.
This study tests an oral medicine called rilzabrutinib to see if it can reduce painful episodes in people with sickle-cell disease. It may be an option if you have regular pain crises and are looking for a new treatment.
This Phase 1 study tests whether nicotinamide, oral tetrahydrouridine, and decitabine can help people with high-risk sickle cell disease. It is mainly a safety-and-dosing study, but it also looks for signs the medicines may improve disease-related problems.
This trial tests CS-206, an experimental therapy for people with sickle cell disease. It aims to reduce severe complications like pain crises, acute chest syndrome, strokes, and other serious events. You may qualify if you have a specific genetic type of sickle cell disease and have experienced complications despite standard treatments.
This trial tests if an intravenous medication called L-citrulline can help treat pain crises in children and young adults with sickle cell disease. Participants receive either the study drug or a placebo while in the hospital for a severe pain episode.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.